A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

OBJECTIVE: Etrolizumab (rhuMAb β7, anti-β7, PRO145223) is a humanised monoclonal antibody targeting the β7 subunit of the heterodimeric integrins α4β7 and αEβ7, which are implicated in leucocyte migration and retention in ulcerative colitis (UC). This randomised phase I study evaluated the safety an...

Descripción completa

Detalles Bibliográficos
Autores principales: Rutgeerts, Paul J, Fedorak, Richard N, Hommes, Daan W, Sturm, Andreas, Baumgart, Daniel C, Bressler, Brian, Schreiber, Stefan, Mansfield, John C, Williams, Marna, Tang, Meina, Visich, Jennifer, Wei, Xiaohui, Keir, Mary, Luca, Diana, Danilenko, Dimitri, Egen, Jackson, O'Byrne, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2013
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711369/
https://www.ncbi.nlm.nih.gov/pubmed/22717454
http://dx.doi.org/10.1136/gutjnl-2011-301769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711369/
https://www.ncbi.nlm.nih.gov/pubmed/22717454
http://dx.doi.org/10.1136/gutjnl-2011-301769

Ejemplares similares